371 related articles for article (PubMed ID: 35404189)
21. Targeting RET alterations in cancer: Recent progress and future directions.
Shabbir A; Kojadinovic A; Shafiq T; Mundi PS
Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304
[TBL] [Abstract][Full Text] [Related]
22. [Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].
Gao Q; Su J; Xiao F; Lin X; Yang J
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):853-861. PubMed ID: 34743497
[TBL] [Abstract][Full Text] [Related]
23. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
24. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
Novello S; Califano R; Reinmuth N; Tamma A; Puri T
Oncologist; 2023 May; 28(5):402-413. PubMed ID: 36821595
[TBL] [Abstract][Full Text] [Related]
25. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
[TBL] [Abstract][Full Text] [Related]
26. Pralsetinib treatment for multiple
Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
[TBL] [Abstract][Full Text] [Related]
27. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with
Bradford D; Larkins E; Mushti SL; Rodriguez L; Skinner AM; Helms WS; Price LSL; Zirkelbach JF; Li Y; Liu J; Charlab R; Turcu FR; Liang D; Ghosh S; Roscoe D; Philip R; Zack-Taylor A; Tang S; Kluetz PG; Beaver JA; Pazdur R; Theoret MR; Singh H
Clin Cancer Res; 2021 Apr; 27(8):2130-2135. PubMed ID: 33239432
[TBL] [Abstract][Full Text] [Related]
28. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
29. [Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)].
; ;
Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):991-1002. PubMed ID: 38110308
[TBL] [Abstract][Full Text] [Related]
30. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
Syed YY
Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
[TBL] [Abstract][Full Text] [Related]
31. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.
Rocco D; Sapio L; Della Gravara L; Naviglio S; Gridelli C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768754
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
[TBL] [Abstract][Full Text] [Related]
34. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
35. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract][Full Text] [Related]
36. Targeting RET alterations in non-small cell lung cancer.
Nishikawa G; Klein MA
Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
[TBL] [Abstract][Full Text] [Related]
37. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
38. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
39. A contemporary review of rearranged during transfection-selective inhibitors.
Liu AW; Liang C; Lee CS
J Oncol Pharm Pract; 2022 Jan; 28(1):175-184. PubMed ID: 34590525
[TBL] [Abstract][Full Text] [Related]
40. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
Gu L; Ji W; Xu Y; Han Y; Jian H
Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
